Inhaled Insulin Afrezza® in Pediatric Patients with Type 1 Diabetes

Description

The purpose of this research study is to test an investigational drug Afrezza® (inhaled insulin) in children and adolescents with T1DM between 4 and 17 years of age. Afrezza® is a rapid acting inhaled insulin, which was approved by Food and Drug Administration (FDA) for the treatment of diabetes in adults. Multiple doses of inhaled insulin will be evaluated over an approximate 4-week period.

Who can participate? Males or females between 4 and 17 years old in good general health, diagnosed with Type 1 Diabetes Mellitus and using insulin daily for at least 1 year

Study procedures you can expect during the study:

  • Interviews about your health
  • Physical examination
  • Blood and urine samples collection for testing
  • Lung function test
  • Electrocardiogram
  • Afrezza® administration
  • Subject Diary

If interested: Please email diabetesresearch@email.chop.edu or call 267-426-3909. IRB 15-012292

For More Information

Contact Us Online

Call (267) 426-6846